These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29744075)

  • 1. Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?
    Cima LN; Lambrescu IM; Stejereanu L; Colita A; Or R; Fica S
    Clin Case Rep; 2018 May; 6(5):867-870. PubMed ID: 29744075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Not All Orbitopathy Is Graves': Discussion of Cases and Review of Literature.
    Boddu N; Jumani M; Wadhwa V; Bajaj G; Faas F
    Front Endocrinol (Lausanne); 2017; 8():184. PubMed ID: 28824545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis.
    Le Moli R; Russo M; Malandrino P; Vella V; Belfiore A; Frasca F
    Hormones (Athens); 2021 Mar; 20(1):161-165. PubMed ID: 32500462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.
    Sabini E; Ionni I; Rocchi R; Vitti P; Marcocci C; Marinò M
    Eur Thyroid J; 2018 Jan; 7(1):51-54. PubMed ID: 29594055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.
    Muller I; Moran C; Lecumberri B; Decallonne B; Robertson N; Jones J; Dayan CM
    Eur Thyroid J; 2019 Jul; 8(4):173-185. PubMed ID: 31602359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
    Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
    Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer aided volumetric assessment of orbital structures in patients with Graves' orbitopathy: correlation with serum thyroid antiperoxidase antibodies and disease activity.
    Paniagua L; Bande MF; Abalo-Lojo JM; Gonzalez F
    Int Ophthalmol; 2023 Sep; 43(9):3377-3384. PubMed ID: 37338774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
    Genere N; Stan MN
    Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
    Perros P; Žarković MP; Panagiotou GC; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi AM; Nardi M; Brix TH; Covelli D; Daumerie C; Eckstein AK; Fichter N; Ćirić S; Hegedüs L; Kahaly GJ; Konuk O; Lareida JJ; Okosieme OE; Leo M; Mathiopoulou L; Clarke L; Menconi F; Morris DS; Orgiazzi J; Pitz S; Salvi M; Muller I; Knežević M; Wiersinga WM; Currò N; Dayan CM; Marcocci C; Marinò M; Möller L; Pearce SH; Törüner F; Bernard M;
    J Endocrinol Invest; 2020 Dec; 43(12):1717-1722. PubMed ID: 32474767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.
    Erdei A; Steiber Z; Molnar C; Berenyi E; Nagy EV
    BMC Ophthalmol; 2018 Jan; 18(1):5. PubMed ID: 29329570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Graves' Disease during Immune Reconstitution following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation in a Boy Carrying Germline
    Ip PP; Fang LH; Shen YL; Tung KC; Lai MT; Juan LY; Chen LY; Chen RL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid Receptor Antibody and the Development of Graves' Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves' Orbitopathy in post-iodine ablation hypothyroid patient.
    Christina E; Budiawan H; Indrawati H; Affandi Soeriadi E; Nugrahadi T; Kartamihardja AH
    Asia Ocean J Nucl Med Biol; 2023; 11(2):185-190. PubMed ID: 37324233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
    Siderova M; Hristozov K; Tsukeva A
    Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exophthalmos and multinodular goitre, an unusual combination.
    Okolie K; Chen D; Ghabrial R; Schmidli R
    Endocrinol Diabetes Metab Case Rep; 2019 May; 2019():. PubMed ID: 31051471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.